title: Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis.
abstract: With the current rise in multiresistant gram-negative bacteria, carbapenems are more frequently used. Surprisingly, limited data exist on the pharmacokinetics of meropenem in peritoneal dialysis (PD)-related peritonitis. We report on the pharmacokinetics of repeated intraperitoneal (IP) meropenem during 21 days as treatment for polymicrobial multiresistent PD-related peritonitis.Our current report supports daily doses of 125 mg/L intraperitoneal meropenem in all bags as an effective and safe modality in the treatment of PD-associated peritonitis with multiresistant microorganisms. No signs of over- or underdosing were found based on serial drug concentration measurements at fixed time points up to 21 days.
authors.affiliation: Internal Medicine/Nephrology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands c.w.h.defijter@olvg.nl.
authors.forename: Caroline W H
authors.initials: CW
authors.lastname: de Fijter
authors.affiliation: Internal Medicine/Nephrology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
authors.forename: Lily
authors.initials: L
authors.lastname: Jakulj
authors.affiliation: Internal Medicine/Nephrology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
authors.forename: Fariba
authors.initials: F
authors.lastname: Amiri
authors.affiliation: Pharmacy, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
authors.forename: Anthe
authors.initials: A
authors.lastname: Zandvliet
authors.affiliation: Pharmacy, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
authors.forename: Eric
authors.initials: E
authors.lastname: Franssen
mesh_terms: D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy*; D000077731:Meropenem; D061214:Patient Safety; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects* / Q000379:methods*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D013845:Thienamycins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077731:Meropenem
keywords: Carbapenems; PD-related peritonitis; meropenem